BHCM
VERV

Brevan Howard Capital Management’s Verve Therapeutics VERV Stock Holding History

Brevan Howard Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,754
Closed -$166K – 2306
2025
Q2 		$166K Sell
14,754
-52,259
-78% -$298K ﹤0.01% 1742
2025
Q1 		$306K Buy
+67,013
New +$449K ﹤0.01% 859
2024
Q3 		– Sell
-23,782
Closed -$116K – 1459
2024
Q2 		$116K Buy
+23,782
New +$149K ﹤0.01% 957
2024
Q1 		– Sell
-14,741
Closed -$205K – 1371
2023
Q4 		$205K Buy
+14,741
New +$183K ﹤0.01% 872

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Brevan Howard Capital Management's VERV Position: Q3 2025 in Review

Brevan Howard Capital Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 14,754 shares — an estimated $166K sold.

Brevan Howard Capital Management first reported a position in VERV in Q4 2023 and held it in 4 quarters. The position peaked at $306K in Q1 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Brevan Howard Capital Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 14,754 Verve Therapeutics shares in Q3 2025, an estimated $166K.
  • Brevan Howard Capital Management first reported a position in Verve Therapeutics in Q4 2023 and held it in 4 quarters.
  • Brevan Howard Capital Management's Verve Therapeutics position peaked at $306K in Q1 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Brevan Howard Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.